Last reviewed · How we verify
EGCG, FA, HA, B12
At a glance
| Generic name | EGCG, FA, HA, B12 |
|---|---|
| Also known as | Pervistop |
| Sponsor | Centro di Ricerca Clinica Salentino |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- The Effect of Natural Molecules on HPV Infection (NA)
- Epigallocatechin Gallate and Other Antural Compounds in HPV Infections (PHASE2)
- Effect of Natural Compounds on the Severity of HPV-induced Cervical Lesions (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EGCG, FA, HA, B12 CI brief — competitive landscape report
- EGCG, FA, HA, B12 updates RSS · CI watch RSS
- Centro di Ricerca Clinica Salentino portfolio CI